Vusolimogene oderparepvec and pembrolizumab for angiosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—an injected virus that attacks cancer cells and an immunotherapy that helps the immune system fight the cancer—for people with angiosarcoma that has spread or cannot be removed and has not responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of skin cancer called angiosarcoma that has spread or cannot be removed by surgery.
- Your cancer has grown during or after at least one immunotherapy treatment and one chemotherapy regimen (like taxane or anthracycline).
- You have at least one tumor that can be measured and is at least 1 cm in size.
- You are 18 years or older.
- You are generally in good health, able to care for yourself, and have adequate organ function.
- You have not had an oncolytic virus treatment before and do not have certain infections or conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining propranolol (a blood-pressure/heart medicine) with pembrolizumab (an immune therapy) can help people with advanced angiosarcoma or undifferentiated pleomorphic sarcoma that has progressed after first-line chemotherapy. It aims to slow tumor growth and improve outcomes while also studying tumor markers from your biopsy tissue.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
This trial tests a new drug called ivonescimab for people with advanced skin angiosarcoma that has spread or cannot be removed by surgery. You must have already tried a chemotherapy drug like paclitaxel or docetaxel. The goal is to see if ivonescimab can help shrink or slow the cancer.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Angiosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.